Isofol Medical Ab

Anders Vedin

Bengt Gustavsson

Göran U Carlsson

Elisabeth Odin

Yvonne Wettergren

Gunnel E Sundén

Per L Lindberg

Per Lennart Lindberg

Gunnel Elisabet SUNDÉN

The present invention provides methods for increasing plasma dUrd levels comprising the administration of 6R-MTHF. The methods of increasing plasma dUrd increase dUrd levels compared to equimolar concentrations of LV. The present invention also provides methods for increasing TS inhibition comprising the administration of 6R-MTHF. The present invention also provides methods for increasing TS inhibition comprising the administration of 6R-MTHF.

Methods for increasing blood plasma 2'-deoxyuridine (dUrd) and thymidylate synthase inhibition

The present invention relates to the treatment of solid tumors in humans such as cancer, especially colorectal cancer (CRC), which involves administering the diastereomerically pure folate adjuvant [6R]-5,10-methylenetetrahydrofolate in 5-fluorouracil (5-FU) based chemotherapy.

[6R]&#x2014;MTHF&#x2014;an efficient folate alternative in 5-fluorouracil based chemotherapy

The present invention relates to the treatment of solid tumors in humans such as cancer, especially colorectal cancer (CRC), which involves administering multiple boluses of the diastereomerically pure folate adjuvant [6R]-5,10-methylenetetrahydrofolate in 5-fluorouracil (5-FU) based chemotherapy.

[6R]-MTHF multiple bolus administration in 5-fluorouracil based chemotherapy

Growing community of inventors

Göteborg, Sweden

Anders Vedin